Jacobio Pharmaceuticals Group Co. Ltd.
Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies. Its clinical stage candidates include Glecirasib (JAB-21822), a KRAS G12C inhibitor under various stage studies for indications, such as NSCLC, PDAC, CRC, and other solid tumors; Sitneprotafib (JAB-3312), an SHP2 inhibitor that is in Phase III trials for… Read more
Jacobio Pharmaceuticals Group Co. Ltd. (JBPHF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2023: -0.087x
Based on the latest financial reports, Jacobio Pharmaceuticals Group Co. Ltd. (JBPHF) has a cash flow conversion efficiency ratio of -0.087x as of June 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-109.88 Million) by net assets ($1.26 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Jacobio Pharmaceuticals Group Co. Ltd. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Jacobio Pharmaceuticals Group Co. Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Jacobio Pharmaceuticals Group Co. Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jacobio Pharmaceuticals Group Co. Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Changshu Tongrun Auto
SHG:603201
|
N/A |
|
Ard Grup Bilisim Teknolojileri AS
IS:ARDYZ
|
0.044x |
|
Security National Financial
NASDAQ:SNFCA
|
0.070x |
|
SUNDARAM CLAYTON LTD
NSE:SUNCLAY
|
-0.008x |
|
Silicius Real Estate SOCIMI S.A.
MC:YSIL
|
-0.004x |
|
Powerlogics Co. Ltd
KQ:047310
|
0.099x |
|
MNRB Holdings Bhd
KLSE:6459
|
0.065x |
|
WHA Utilities and Power Public Company Limited
BK:WHAUP
|
0.028x |
Annual Cash Flow Conversion Efficiency for Jacobio Pharmaceuticals Group Co. Ltd. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Jacobio Pharmaceuticals Group Co. Ltd. from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $923.18 Million | $-74.12 Million | -0.080x | +76.34% |
| 2023-12-31 | $1.07 Billion | $-364.20 Million | -0.339x | -48.82% |
| 2022-12-31 | $1.28 Billion | $-292.42 Million | -0.228x | -153.07% |
| 2021-12-31 | $1.64 Billion | $-147.49 Million | -0.090x | -304.16% |
| 2020-12-31 | $1.79 Billion | $78.83 Million | 0.044x | -81.65% |
| 2019-12-31 | $-470.08 Million | $-113.03 Million | 0.240x | -- |